---

Comparing palonosetron and lignocaine pretreatment with venous occlusion on reducing rocuronium associated withdrawal movements. A double blinded randomized control trial

---

Original Article

Author Details : Kamal Kajal, Jesto Kurian, Ishwar Bhukkal, Amarjyoti Hazarika*, Shiv Lal Soni

Volume : 5, Issue : 3, Year : 2018

Article Page : 110-115

https://doi.org/10.18231/2393-9087.2018.0024

Suggest article by email

Get Permission

---

Abstract

Introduction: Use of rocuronium has been associated with withdrawal movements of injected arm during its administration. Our study is to compare the effectiveness of palonosetron vs. lignocaine pretreatment with venous occlusion on reducing withdrawal movements associated with rocuronium injection.
Materials and Methods: This prospective randomized double blind trial includes 150 patients aged between 18 and 65 years undergoing elective day-care surgeries. Patients were randomly divided into 3 groups of 50 patients each with assistance from computer generated random number table. Group P received palonosetron 075mg, Group L received Lignocaine 30 mg and Group S received Normal saline as pretreatment. The degree of withdrawal of limb was graded on four-point scale. Haemodynamic changes namely HR and MAP following administration of study drugs and complications following administration of the study drugs like urticaria, wheal and rash were also monitored.
Results: Overall incidence of rocuronium induced withdrawal movements was significantly more in-group S (84%) than other study groups (p<0> Conclusion: Study demonstrated that palonosetron pretreatment and venous occlusion has reduced rocuronium induced withdrawal movements more effectively than lignocaine.

Keywords: Palanosetron, Rocuronium, Withdrawal movements, Lignocaine.

How to cite : Kajal K , Kurian J, Bhukkal I, Hazarika A, Soni S L, Comparing palonosetron and lignocaine pretreatment with venous occlusion on reducing rocuronium associated withdrawal movements. A double blinded randomized control trial. Indian J Pharm Pharmacol 2018;5(3):110-115

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.